Search clinical trials for: MyoVista

Total 16 results

Lundquist Institute for Biomedical Innovation at...
Heart Test Laboratories, Inc.

Completed

MyoVista Measurements in Patients With Atherosclerosis and CAD

Atherosclerosis | Coronary Artery Disease (CAD)

United States
Heart Test Laboratories, Inc.

Active, not recruiting

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

Health Screening

United States
Heart Test Laboratories, Inc.

Active, not recruiting

MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram

Cardiac Disease

United States
Great Western Hospitals NHS Foundation Trust
Northern Care Alliance NHS Foundation Trust; North Tees and Hartlepool NHS... and other collaborators

Not yet recruiting

Myovista vs NT Pro-BNP Heart Failure Referral Tool

Heart Failure

United Kingdom
Royal Cornwall Hospitals Trust

Terminated

The MyoVista Angiography Angioplasty Percutaneous Coronary Intervention Trial (MAAP)

Coronary Artery Disease | Diastolic Dysfunction

United Kingdom
Icahn School of Medicine at Mount Sinai
Heart Test Laboratories, Inc.

Completed

Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease

Coronary Artery Disease

United States
NeoVista

Unknown

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy (MERITAGE)

Age Related Macular Degeneration

United Kingdom, Israel, United States
NeoVista

Completed

A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy (ROSE)

Wet Age-related Macular Degeneration

United States
Ophthotech Corporation

Terminated

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Age-related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Israel, United States, Germany, Denmark, France, Turkey, Hungary, Colombia, Australia, Argentina, Spain
Retinal Consultants of Arizona
Ophthotech Corporation

Completed

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
National Cancer Institute (NCI)

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage... and other conditions

United States
University of Southern California

Recruiting

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Soft Tissue Sarcoma | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Merkel Cell Carcinoma | Unresectable Melanoma | Unresectable Breast Carcinoma | Bone Sarcoma | Sarcoma,Soft Tissue | Metastatic Breast Carcinoma | Cutaneous Squamous Cell Carcinoma and other conditions

United States

Search clinical trials for: MyoVista

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations